Tags

Type your tag names separated by a space and hit enter

Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Clin Endocrinol (Oxf). 2017 Jul; 87(1):73-79.CE

Abstract

OBJECTIVE

We assessed the associations between FDG uptake in primary papillary thyroid carcinomas (PTCs) and clinicopathological features, including the BRAF V600E mutation, using quantitative and qualitative analyses of preoperative PET/CT data.

DESIGN AND PATIENTS

This was a retrospective review of 106 patients with PTC who underwent PET/CT scans between February 2009 and January 2011 before undergoing total thyroidectomy. Data collected from surgical specimens were compared with FDG uptake in the primary tumour using quantitative and qualitative analyses of preoperative PET/CT data. Clinicopathological data included the primary tumour size, subtype, capsular invasion, extrathyroid extension, multifocality, BRAF V600E mutation status, lymph node metastasis and distant metastasis.

RESULTS

The SUVmax of the primary tumour was significantly higher in patients with a primary tumour >1 cm, extrathyroid extension or the BRAF V600E mutation than in patients without these features (P<.001, .049 and <.001). Univariate analyses showed that primary tumour size, extrathyroid extension and BRAF V600E mutation status were associated with the SUVmax of the PTC. Multivariate analysis indicated that primary tumour size and the BRAF V600E mutation were associated with the SUVmax of the PTC. In a visual assessment, the primary tumour size was larger in FDG-avid than in non-FDG-avid PTCs (P<.001). There was no significant difference in the presence of multifocality, thyroid capsular invasion, extrathyroid extension, BRAF V600E mutation, lymph node metastasis or distant metastasis between FDG-avid and non-FDG-avid PTCs.

CONCLUSIONS

Primary tumour size and the BRAF V600E mutation are significant factors associated with the SUVmax on preoperative PET/CT in patients with PTC.

Authors+Show Affiliations

Department of Radiology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.Department of Nuclear Medicine, Chosun University Hospital, Gwangju, South Korea.Department of Nuclear Medicine, Chosun University Hospital, Gwangju, South Korea.Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28329426

Citation

Choi, Eun Kyoung, et al. "Clinicopathological Characteristics Including BRAF V600E Mutation Status and PET/CT Findings in Papillary Thyroid Carcinoma." Clinical Endocrinology, vol. 87, no. 1, 2017, pp. 73-79.
Choi EK, Chong A, Ha JM, et al. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2017;87(1):73-79.
Choi, E. K., Chong, A., Ha, J. M., Jung, C. K., O, J. H., & Kim, S. H. (2017). Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma. Clinical Endocrinology, 87(1), 73-79. https://doi.org/10.1111/cen.13335
Choi EK, et al. Clinicopathological Characteristics Including BRAF V600E Mutation Status and PET/CT Findings in Papillary Thyroid Carcinoma. Clin Endocrinol (Oxf). 2017;87(1):73-79. PubMed PMID: 28329426.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma. AU - Choi,Eun Kyoung, AU - Chong,Ari, AU - Ha,Jung-Min, AU - Jung,Chan Kwon, AU - O,Joo Hyun, AU - Kim,Sung Hoon, Y1 - 2017/04/18/ PY - 2016/10/05/received PY - 2017/03/07/revised PY - 2017/03/19/accepted PY - 2017/3/23/pubmed PY - 2018/3/20/medline PY - 2017/3/23/entrez KW - BRAF mutation KW - fluorodeoxyglucose F18 KW - positron emission tomography KW - thyroid neoplasms SP - 73 EP - 79 JF - Clinical endocrinology JO - Clin. Endocrinol. (Oxf) VL - 87 IS - 1 N2 - OBJECTIVE: We assessed the associations between FDG uptake in primary papillary thyroid carcinomas (PTCs) and clinicopathological features, including the BRAF V600E mutation, using quantitative and qualitative analyses of preoperative PET/CT data. DESIGN AND PATIENTS: This was a retrospective review of 106 patients with PTC who underwent PET/CT scans between February 2009 and January 2011 before undergoing total thyroidectomy. Data collected from surgical specimens were compared with FDG uptake in the primary tumour using quantitative and qualitative analyses of preoperative PET/CT data. Clinicopathological data included the primary tumour size, subtype, capsular invasion, extrathyroid extension, multifocality, BRAF V600E mutation status, lymph node metastasis and distant metastasis. RESULTS: The SUVmax of the primary tumour was significantly higher in patients with a primary tumour >1 cm, extrathyroid extension or the BRAF V600E mutation than in patients without these features (P<.001, .049 and <.001). Univariate analyses showed that primary tumour size, extrathyroid extension and BRAF V600E mutation status were associated with the SUVmax of the PTC. Multivariate analysis indicated that primary tumour size and the BRAF V600E mutation were associated with the SUVmax of the PTC. In a visual assessment, the primary tumour size was larger in FDG-avid than in non-FDG-avid PTCs (P<.001). There was no significant difference in the presence of multifocality, thyroid capsular invasion, extrathyroid extension, BRAF V600E mutation, lymph node metastasis or distant metastasis between FDG-avid and non-FDG-avid PTCs. CONCLUSIONS: Primary tumour size and the BRAF V600E mutation are significant factors associated with the SUVmax on preoperative PET/CT in patients with PTC. SN - 1365-2265 UR - https://www.unboundmedicine.com/medline/citation/28329426/Clinicopathological_characteristics_including_BRAF_V600E_mutation_status_and_PET/CT_findings_in_papillary_thyroid_carcinoma_ L2 - https://doi.org/10.1111/cen.13335 DB - PRIME DP - Unbound Medicine ER -